Alkem Laboratories Limited is an Indian pharmaceutical company

based in Mumbai, Maharashtra, India. Established in 1973 by Mr. Samprada Singh, the company
manufactures and sells branded generics, generic drugs, active pharmaceutical ingredient (APIs)
and neutraceuticals both in India and internationally in 55 countries (mainly the US), including
Australia, Europe, South East Asia, Latin America, Africa and CIS.

The company has a wide ranging presence in the acute and chronic therapeutic segments such as
Anti-infectives, Gastro-intestinal, Pain Management, Vitamins, Minerals and Nutrition, Central
Nervous System, Anti-diabetic, Anti-osteoporosis, Anti-malarial, Cardiovascular,
Immunosuppressants and Nutraceutical segments.

As per its September 2015 figures, the company:

 Had a portfolio of 736 branded generic drugs

 Had 13 of its brands featured among the top 300 brands in India
 Was one of India’s top 10 pharmaceutical companies (in terms of domestic sales) for the
past 12 years
 Had 16 manufacturing facilities (all cGMP compliant):
o 14 were in India
o 2 were in US
o 5 facilities were US FDA, TGA, UK MHRA approved
 Had 4 R&D facilities (2 in India and 2 in the US) employing 438 scientists

Ranked 5 in the Indian pharmaceutical market in terms of domestic sales in the fiscal year 2015,
the company enjoys a domestic market leadership in the following segments

 Ranked 1 in anti-infectives, with an 11.2% market share

 Ranked 3 in gastro-intestinals with a 5.6% market share
 Ranked 3 in pain/analgesics with a 5% market share
 Ranked among the top 10 in vitamins, minerals, nutrients and gynecolog

Alkem Laboratories Limited is listed on the National Stock Exchange of India (NSE) and the
Bombay Stock Exchange (BSE).
VISION
Alkem is working towards becoming one of the top 5 pharmaceutical companies in India by 2014. Alkem
further wishes to achieve this milestone through organic growth as well as through its affiliations with
international associations, partnerships and strategic alliances.

Alkem’s vision, as an organization, is to achieve value driven leadership through consistent hard work in
developing enduring quality products, marked by exceptional service.

Mission
To be a good corporate citizen and not only add value in our core competency areas of
Pharma but also serve the community at large through social, educational and
environmental initiatives that would establish strong foundations for a better tomorrow.

VALUES
The belief that quality healthcare services have no boundaries in a global world drives Alkem to deliver
the best healthcare products in its markets. A ‘People-First Policy’ ensures that Alkem meets and
surpasses the evolving expectations of its customers, at all times.
Objectives
 Not just curing lives but helping
Enjoy every moment
 Life care with constant focus on innovation & research
 Life care for fulfillment of dream
 Extending life care beyond boundaries
 Not just curing lives but helping enjoy every moment
Company products

Division Product Name Composition

ALKEM A TO Z GOLD NS SOFT
MULTIVITAMIN, MULTIMINERALS
ACE GELATIN CAPS (15S)
ALKEM AMOXICILLIN 250 + CLAVULANIC ACID
CLAVAM 375
ACE 125MG
ALKEM AMOXICILLIN 500 + CLAVULANIC ACID
CLAVAM 625
ACE 125MG
ALKEM AMOXYCILLIN 200MG + CLAV
CLAVAM BID DRY SYRUP
ACE 28.5MG/5ML
ALKEM
CLAVAM DROPS AMOXYCILLIN 80MG + CLAV 11.4MG/ML
ACE
ALKEM AMOXYCILLIN 125MG + CLAVULANIC
CLAVAM DRY SYRUP
ACE ACID 31.25MG / 5ML DRY SYRUP
ALKEM
CLAVAM DT AMOXYCILLIN 200MG + CLAV 28.5MG DT
ACE
ALKEM
CLAVAM FORTE DS 3 30 ML. AMOXYCILLIN 400MG + CLAV 57MG/5ML
ACE
ALKEM AMOXYCILLIN 1000MG + CLAVULANIC
CLAVAM INJ 1.2GM
ACE ACID 200MG
ALKEM AMOXYCILLIN 125MG + CLAVULANIC
CLAVAM INJ 150MG
ACE ACID 25MG
ALKEM CLAVAM INJ
AMOXYCILLIN 250MG + CLAVULANIC ACID 50MG
ACE 300MG
ALKEM
CLAVAM XR AMOXYCILLIN 1000MG + CLAVULANIC ACID 62.5MG
ACE
ALKEM ACTIVATED DIMETHICONE 40MG + DILL OIL 0.005ML +
COLPEP DROPS
ACE FENNEL OIL 0.0007MG / ML SYRUP
ALKEM DICYCLOMINE HCl 10MG + ACTIVATED DIMETHICONE
COLPEP SUSP
ACE 40MG / 5ML SUSP
ALKEM
EMTY Lactulose 10gm / 15ml Solution
ACE
ALKEM FREEAIR
FLUTICASONE FUROATE 27.5MG NASAL SPRAY
ACE NASAL SPRAY
HEMFER FERROUS GLYCINE SULPHATE 50MG (EQUI. IRON) +
ALKEM
CAPSULES FOLIC ACID 0.5MG + CYANOCOBALAMINE 7.5MCG + ZINC
ACE
(NEW)(30'S) SULPHATE 5MG (EQUI. ZINC)
FERROUS GLYCINE SULPHATE 10MG (IRON EQUI.) +
ALKEM HEMFER
FOLIC ACID 100MCG + CYANOCOBALAMINE 1.5MCG / ML
ACE DROPS
DROPS
Division Product Name Composition
ALKEM HEMFER
FERRIC HYDROXIDE WITH SUCROSE 100MG (EQUI. IRON)
ACE INJECTION
FERROUS GLYCINE SULPHATE 25MG (IRON EQUI.) +
ALKEM HEMFER KID FOLIC ACID 0.25MG + CYANOCOBALAMINE 3.75MCG +
ACE SYRUP ZINC SULPHATE MONOHYDRATE 3.5MG (ZINC EQUI.) / 5
ML DROPS
FERROUS GLYCINE SULPHATE 50MG (EQUI. IRON)
ALKEM + FOLIC ACID 0.5MG + CYANOCOBALAMINE
HEMFER SYRUP
ACE 7.5MCG + ZINC SULPHATE 2.5MG (EQUI. ZINC) + D-
BIOTIN 100MCG / 15ML
FERROUS GLYICINE SULPHATE 50MG (EQUI.
HEMFER SYRUP
ALKEM IRON) + FOLIC ACID 0.5MG +
(NEPAL SUPPLY)
ACE CYANOCOBALAMINE 7.5MCG + ZINC SULPHATE
200ML
15MG (EQUI. ZINC) / 5ML
ALKEM FERROUS ASCORBATE 100MG + FOLIC ACID
HEMFER-XT
ACE 1.5MG
ALKEM
LINCEF CEFIXIME 200MG + LINEZOLID 600MG TABS
ACE
ALKEM LINOKEM 600MG
LINEZOLID 600MG TABS
ACE TABLETS (10'S)
ALKEM LINOKEM I.V. 600MG
LINEZOLID 600MG / 300ML INFUSION
ACE INJECTION (300ML)
ALKEM PAN 40MG INJECTION
PANTOPRAZOLE 40MG INJ
ACE (VIAL)
ALKEM
PAN - D CAPS 10'S PANTOPRAZOLE 40MG + DOMPERIDONE 30MG
ACE
ALKEM PAN 20 MD TABLETS
PANTOPRAZOLE 20MG MOUTH DISSOLVING TABS
ACE (10'S)
ALKEM
PAN IT CAPSULES 10'S PANTOPRAZOLE 40MG + ITOPRIDE 150MG
ACE
OUR SUBSIDIARIES
Our Company has the following subsidiaries:
Indian Subsidiaries:
1. Cachet Pharmaceuticals Private Limited;

2. Indchemie Health Specialities Private Limited;

3. Enzene Biosciences Limited; and

4. Alkem Real Estate LLP.

Foreign Subsidiaries:
5. Alkem Laboratories Korea, Inc., Korea;

6. Alkem Laboratories (Nigeria) Limited, Nigeria;

7. Alkem Laboratories (Pty) Limited, South Africa;

8. Alkem Laboratories Corporation, Philippines;

9. Alkem Pharma GmbH, Germany;

10. Ascend Laboratories LLC, U.S.;

11. Ascend Laboratories Sdn Bhd, Malaysia;

12. Ascend Laboratories SpA, Chile;

13. Ascend Laboratories (UK) Limited, UK;

14. Pharmacor Pty Ltd, Australia;

15. Pharmacor Limited, Kenya;

16. ThePharmaNetwork LLC, U.S.;

17. The PharmaNetwork LLP, Kazakhstan;

18. S&B Holdings BV, The Netherlands; and

19. S&B Pharma Inc, Delaware, U.S.

Alkem Laboratories Ltd. - Strategic SWOT Analysis Review
Summary

Alkem Laboratories Ltd. (Alkem) is a pharmaceutical company that develops, manufactures, and
markets generic and specialty pharmaceutical products. The company’s products include active
pharmaceutical ingredients, generic products, branded products and nutraceuticals. Alkem
provides drugs for acute and chronic diseases such as central nervous system disorders, gastro-
intestinal infections, diabetes, malaria, pain, cardiovascular diseases and immune disorders. It
offers vitamins, minerals and nutrition products. The company distributes its products a wide
network of distributors all over India. It exports products to Europe, Australia, South-East Asia,
North America, South America, Russia-CIS and Africa. Alkem is headquartered in Mumbai,
Maharashtra, India.

Alkem Laboratories Ltd. (ALKEM) - Pharmaceuticals & Healthcare - Deals and Alliances
Profile provides you comprehensive data and trend analysis of the company's Mergers and
Acquisitions (M&As), partnerships and financings. The report provides detailed information on
Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and
Partnership transactions recorded by the company over a five year period. The report offers
detailed comparative data on the number of deals and their value categorized into deal types,
sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack
deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and
Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and
value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value
reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value
reported by the company by region, which includes North America, Europe, Asia Pacific, the
Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value
reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief
summary, deal type, deal rationale; and deal financials and target Company’s (major public
companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and
subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the
company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by
business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you
understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to
understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal
rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential
customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key
executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important
events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals
are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Competitive advantage
Market leadership in various therapeutic areas and ability to build market leading
brands in the domestic market

We are one of India’s leading pharmaceutical companies and were ranked fifth in the
Indian pharmaceutical market in terms of domestic sales for fiscal year 2015
(Source:IMS SSA MAT March 2015). For fiscal year 2015, we were the leader in the
largest therapeutic area (anti-infective) with a 11.2% market share and were ranked
third in terms of market share for both the gastro-intestinal (with a market share of
5.6%) and pain/analgesics therapeutic areas (with a market share of 5.0%), in each
case, in India (Source:IMS SSA MAT March 2015). Our revenuesfrom the anti-
infectives, gastro-intestinal and pain/analgesics therapeutic areas in India grew at a
CAGR of 10.1%, 17.5% and 12.0% in the period from fiscal year 2011 to fiscal year
2015 (Source:IMS SSA MAT March 2015). In the same period, these therapeutic areas
in India as a whole grew at a lower CAGR of 6.8%, 12.8% and 10.9%, respectively
(Source:IMS SSA MAT March 2015). We are also among the top ten companies in the
vitamins, m inerals, nutrients and gynaecology therapeutic areas in terms of Indian
market share for March 2015 (Source:IMS SSA MAT March 2015). According to IMS
Health, we were the third-fastest growing company in terms of sales in this period
among the ten largest pharmaceutical companies in the Indian domestic formulations
market.

Net revenues from our domestic operations grew at a CAGR of 17.6% in the period
from March 31, 2011 to March 31, 2015.

Our established record of strong performance and reputation for quality products in
various therapeutic areas has helped us build reputable brands in thepharmaceutical
market in India. For instance, our anti-infective brand Taxim was the first anti-infect
ive brand in India to cross 1,000 million in sales in a fiscal year (fiscal year 2006)
(Source:IMS Health). Further, we had the highest number of brands (five) among the
top 50 brands (along with another leading pharmaceutical company) in the
Indianpharmaceutical industry for fiscal year 2015 and also had 13 brands among
the top 300 brands in the Indian pharmaceutical industry for fiscal year 2015
(Source:IMS SSA MAT March 2015). The table below shows our key brands in
various sales ranges for the fiscal year 2015:

Extensive sales, marketing and distribution network in India

We have strong sales, marketing and distribution capabilities in India. Our marketing
and distribution network in India comprises a field force of 5,856
medicalrepresentatives. As a result of our strong sales, marketing and distribution
capabilities, our products were prescribed by an estimated 210,885
prescribers(constituting 70.7% of total prescribers, as defined by IMS) across
various specialties in fiscal year 2015 (Source:IMS Health). Our medical
representatives cover all states in India, including rural areas. As of June 30,
2015,our domestic distribution network includes 39 sales depots, 55 clearing and
forwarding (“C&F”) agents, 15 consignees and eight central warehouses
covering6,576 stockists.We also market our products to
varioushospitals,government institutions and medical institutions.

Strong research and development capabilities which enhance our portfolio

As of June 30, 2015, we employed 483scientists working on various drug products

and substances in India and the United States. Our research and development
department carries out process development, formulation development and
analytical research for our domestic and international markets. In addition, we also
have a regulatory affairs team, which is responsible for various filings and approvals
related to our products in India and internationally. We also have a dedicated in-
house team ofintellectual property experts, who work towards understanding and
filing with respect to intellectual property rights of our products and processes in
various geographical markets.

Fast growing and established international operations

Having established ourselves in the Indian pharmaceuticals market, we have

expanded internationally through both organic growth and certain strategic
acquisitions. The United States is the key focus market for our international
operations. We market and sell our products in the United States under our brand “
Ascend”to major pharmacy chains’ stores, wholesalers, managed care companies,
distributors, food and grocery stores and pharmaceutical retailers. Ascend currently
sells 17 products in the market, out of which 12 are our productsand five are in-
licensed from third parties.For fiscal year 2015, ThePharmaNetwork LLC’s
consolidated netrevenues(through Ascend)were `6,459.7 million. Further, we own
two manufacturing and two R&D facilities in the United States, that we believe
provides us with the infrastructure required to support the growth in our operations in
the United States

Geographically diversified manufacturing facilities accredited by

international regulatory agencies

We operate 14 manufacturing facilities in India, three of which are USFDA approved

and also have other key approvals from international regulatory agencies such as
TGA Australia and UK-MHRA among others for certain of our facilities. Some of our
manufacturing plants enjoy excise and income tax benefits that are available for
different periods. We also have two manufacturing facilities in the United States. Our
facilities implement current good manufacturing practices (“cGMP”).
Our Strategy

Consolidate and further grow our domestic sales

We intend to continue to consolidate our market leadership positions in therapeutic areas such
as anti-infective, pain and gastroenterology and aim for growth in these areas through the
following initiatives:
focus on brand building and driving the growth of focused set of our brands with high growth
potential;
identification of gaps in our product portfolio for the introduction of new products;
growth in prescriptions and prescriber base in key specialty areas;
invest in the training and effectiveness of our field force; and
increasing our market shares in those geographies where our market shares are lower than the
national average.

Continue to grow our business in our international focus markets

As part of our growth strategy for the United States, we intend to enhance our product portfolio
by accelerating ANDA filings. We intend to further grow our United States operations through
our Subsidiary Ascend, by leveraging its established relationships with key retail and national
accounts. In addition to products manufactured by us, Ascend will also continue to expand its
product portfolio by in-licensing products from third parties. Further, we intend to market and sell
drugs/products that we develop for the United States in other developed and emerging markets.

Use of strategic international and domestic acquisitions and partnership arrangements

to enhance growth

In the past, we have used a combination of organic initiatives and acquisitions to drive growth,
and we intend to continue to use this strategy in the future. We have undertaken acquisitions as
part of our entry strategy in to new geographies or new market segments. For instance, in July
2010, we acquired The Pharma network LLC in the United States, the holding company of
Ascend Laboratories LLC. The Pharma network LLC provided us with the commercial platform
through which we were able to market and sell our portfolio of products in the United States.
manufacturing semi-solids, liquid and nasals in the United States. We intend to continue to
actively seek and evaluate potential acquisitions of brands, companies or assets that will
enhance our capabilities.As regards our international business, we plan to continue to acquire
targets to enhance our capabilities, enter new market segments and expand our presence in our
focus markets.
Our Operations

We are a leading, Indian pharmaceutical company with global operations, engaged

in the development, manufactureand sale of pharmaceuticals. We produce high-
quality branded generics, generic drugs, APIs, and nutritional supplements, which
we market in India and 55 countries, primarily the United States. We organize our
business into domestic (i.e. Indian) and international operations.

Our Domestic Operations

We have grown significantly since our incorporation in 1973. For fiscal year 2015,we
were the fifth largest pharmaceutical company in India in terms of domestic sales,
according to IMS Health. Our domestic business has grown at a CAGR of 14.2% in
the period from fiscal year 2011 to fiscal year 2015, as compared to Indian
pharmaceutical industry which grew at a CAGR of 12.2% (
Source: IMS SSA MAT March 2015). Additionally, we
were the third fastest growing company among top ten domestic companies in
Indiaby sales from fiscal year 2011 to fiscal year 2015(Source: IMS SSA MAT March
2015).
 WHISTLEBLOWER POLICY
OF

ALKEM LABORATORIES LTD

INTRODUCTION & PURPOSE.

ALKEM Laboratories requires its Officers and Employees to observe high standards of
business and personal ethics in the conduct of their duties and responsibilities.
The purpose of this policy is as follows:
1. To encourage and enable employees and volunteers of the Company to report any
action or suspected action taken within the Company that is illegal, fraudulent or in
violation of any adopted policy of the Company.
2. To build and strengthen a culture of transparency and trust within the organization.
This policy applies to any matter which is related to the Company’s business and
does not relate to private acts of an individual not connected to the business of the
Company.

APPLICABILITY.
This policy applies to all the employees of ALKEM, (including outsourced, temporary
and on contract personnel), ex-employees, stakeholders of the Company, including
Vendors (hereinafter referred to as “Whistle Blower”)

VIOLATION, REPORTING IN GOOD FAITH:

All employees and volunteers of the Company are encouraged to report any action or
suspected action taken within the Company that is illegal, fraudulent or in violation of
any adopted policy of the Company.
Anyone reporting a Violation must act in good faith, without malice to the Company or
any individual in the Company, and have reasonable grounds for believing that the
information shared in the report indicates that a Violation has occurred. (Any report
which the complainant has made maliciously or any report which the complainant has
good reason to believe is false will be viewed as a serious disciplinary offense.)
NO RETALIATION.
No employee or volunteer who in good faith reports a Violation or Cooperates in the
investigation of a Violation shall suffer harassment, retaliation or adverse employment
or volunteer consequences. Any individual within the Company who retaliates against
another individual who in good faith has reported a Violation or has cooperated in the
investigation of a Violation is subject to discipline, including termination of employment.
Any individual who reasonably believes he or she has been retaliated against in
violation of this policy shall follow the same procedures as for filing a complaint

REPORTING PROCESS:
If an individual reasonably believes that a Violation has occurred, the individual is
encouraged to share his or her questions, concerns, suggestion or complaints to person
designated by the Company. (Mr. Sujit Shetty – Head Internal Audit is the Compliance
Office for the above policy whose contact no is – 39829630 and email id –
whistleblower@alkem.co.in)
In addition to the above, under exceptional circumstances where a complainant wants to
complain directly to the Chairman of the Audit Committee, he or she may do so at the email
address
rlshenoy18@yahoo.com
.
For any complaints made to the Chairman
directly, it is mandatory for the complainant to disclose their identity and provide their
contact information. The Chairman of the Audit Committee may choose to discuss the
matter with the complainant prior to initiating any review or investigation.

CONFIDENTIALITY:
The Company encourages anyone reporting a Violation to identify himself or herself
when making a report in order to facilitate the investigation of the Violation. However,
reports may be submitted on a confidential basis by the complainant or may be
submitted anonymously by filling out a reporting form and depositing the form in a
designated drop box. (The Drop Box will be installed at all Manufacturing & Research &
Development Location). The same to be opened jointly by Location HR & Finance Head
to be forwarded to Compliance Officer on monthly basis (30
th
of every month)

COMPLIANCE OFFICER; HANDLING REPORTED VIOLATIONS:

The Compliance Officer will notify the complainant and acknowledge receipt of a report
of Violation within 10 business days, but only to the extent that the complainant’s
identity is disclosed or a return address is provided.
The Compliance Officer is responsible for promptly investigating all reported Violations
and for causing appropriate corrective action to be taken if warranted by the
investigation. The complainant will be notified about what actions will be taken, to the
extent reasonably possible and consistent with any privacy or confidentiality limitations.
If no further action or investigation is to follow, an explanation for the decision will be
given to the complainant.
In addition, the Compliance Officer will report to the Executive Directors and Audit
Committee of any reported Violations, the current status of the investigation, and the
outcome or corrective action taken at the conclusion of the investigation.
In the event the Compliance Officer is suspected of having committed a Violation, then
the Violation will be reported to Executive Directors and Audit Committee and the
Violation will be investigated by
designated officer
under close supervision of the
Executive Directors and Audit Committee.
Retention of Documents:
All Protected Disclosures in writing or documented along
with the results of investigation relating ther
eto shall be retained by the Company for a
period of seven years.
Amendment: The Company reserves its right to amend or modify this Policy in wholeor in part,
at any time without assigning any reason whatsoever. However, no such amendment or
modification will be binding on the Employees unless the same is notified
to the employees in writing
Board of Directors

Mr. Samprada Singh

Chairman Emeritus

Mr. Samprada Singh is a respected professional in the Indian pharmaceutical industry having an
overall experience of 42 years. He is one of the co-founders of our Company.
He has received various prestigious awards such as the ‘Life Time Achievement Award’ by
Pharma Business and Technology in 2000, the ‘Lifetime Achievement Award’ at the
Pharmaceutical Leadership Summit 2009, ‘Asian Grid Leadership Lifetime Achievement Award
2006’, the ‘Life Time Contribution Award’ by the Express Pharma Excellence Awards in 2004
and ‘Lifetime Achievement Award” at the 2nd Annual AWACS Awards in Marketing
Excellence, 2015. He has been bestowed with the ‘Pride of Bihar’ award at the Bihar Healthcare
Achievers Awards 2014.
Our Chairman Emeritus, has served on our Board since incorporation.

Mr. Basudeo N. Singh

Executive Chairman

Mr. Basudeo N. Singh is a respected professional in the Indian pharmaceutical industry and has
over 40 years of experience in the Indian pharmaceutical industry. He is the co-founder of our
Company. He was the president of the Indian Drug Manufacturer’s Association for the period
2007 - 2009. He has received Business Leader of the Year 2014 in the 7th Annual
Pharmaceutical Leadership Summit and Pharmaleaders Business Leadership Awards 2014. Our
Executive Chairman, has served on our Board since incorporation.

Mr. Sandeep Singh

Managing Director

Mr. Sandeep Singh joined our board in 2013 and at present he is the Managing Director of our
Company.
Mr. Sandeep Singh, is responsible for International Business, R & D including Biotech, Finance,
Quality & Compliance, API and Formulation Manufacturing facilities for International Business
at our Company.

Mr. Dhananjay Kumar Singh

Joint Managing Director

Mr. Dhananjay Kumar Singh joined our Board in 1988 and at present he is the Joint Managing
Director of our Company.
Mr. Dhananjay Kumar Singh, is responsible for specific Domestic Business units focusing on
Acute and Chronic Therapies in addition to support functions namely Legal and Secretarial,
Purchase, Distribution & Logistics and Human Resources at our Company.
Mr. Balmiki Prasad Singh
Executive Director

Mr. Balmiki Prasad Singh joined our Board in 1988. Prior to being appointed to our Board he
was employed with our Company in various capacities.

Mr. Mritunjay Kumar Singh

Executive Director

Mr. Mritunjay Kumar Singh joined our Board in 1988 and he has been associated with the
management of our Company for a period over 24 years. He is also the managing director of our
Subsidiary, Indchemie Health Specialities Private Limited.
Mr. Mritunjay Kumar Singh, Executive Director, shall be responsible for certain Domestic
Business units focusing on Acute and Chronic Therapies, Generics and Healthcare in addition to
Strategy & Business Development and Manufacturing Facilities for Domestic Business at our
Company.
Dr. Dheeraj Sharma
Independent Director

Dr. Dheeraj Sharma holds a doctoral degree with a major in marketing and a double minor in
psychology and quantitative analysis from Louisiana Tech University. His primary research
interests are “relationships” in business domain. He is a Director of Indian Institute of
Management – Rohtak and a Professor (on lien) at Indian Institute of Management –
Ahmedabad.

He has taught at numerous educational institutions including University of North Texas,

Louisiana Tech University, University of Winnipeg, Ball State University, Athabasca University
and IIM Ahmedabad.

He has also served as consultant or in advisory roles with Ministry of Home Affairs, Ministry of
Defence, Ministry of Youth Affairs and Sports, Ministry of Commerce, Govt. of Gujarat, Govt.
of Punjab and Govt. of Delhi.

Dr Sharma has joined our Board on 26th May, 2017.

Mr. A.K. Purwar

Independent DirectorMr. A.K. Purwar in the past has served as the chairman of State Bank of
India from November, 2002 to May, 2006. Mr. Arun Kumar Purwar was the chairman of Indian
Bank Association during 2005-2006.Mr. Purwar has received various prestigious awards such as
the ‘CEO of the year’ Award from the Institute of Technology and Management in 2004,
“Outstanding Achiever of the year” award from the Indian Banks’ Association in 2004 and
“Finance Man of the Year” award by the Bombay Management Association in 2006.
Mr. Purwar joined our Board in 2015.

Mr. A.M. Prasad

Independent Director

Mr. A. M. Prasad retired from the Indian Revenue Service after serving the Government of India
for a period of 37 years.
Mr. Prasad has held several key positions in the Government including Special Secretary to GoI
and Director General, Central Economic Intelligence Bureau, Member of the Central Board of
Excise and Customs, Chief Commissioner, Central Excise and Customs, Maharashtra.
Mr. Prasad joined our Board in 2015.

Mr. R. L. Shenoy
Independent DirectorMr. R. L. Shenoy has was earlier the whole-time director- finance and
legal and company secretary, in Merck Limited, India, (formerly known as E. Merck
(India)Limited).
Mr. Shenoy is a qualified Chartered Accountant, Cost Accountants and Company Secretaries. He
is also an Associate Member of the Indian Institute of Bankers (C.A.IIB).
Mr. Shenoy joined our Board in 2015.
Ms. Sangeeta K. Singh
Independent Director

Ms. Sangeeta Singh has earlier served as executive director in KPMG in the capacity of head of
human resource for India
Ms. Singh joined our Board in 2015.

Ms. Sudha Ravi

Independent Director

Ms. Sudha Ravi has over 30 years of experience across banking and financial services and is
currently an executive director (not on board) of Piramal Fund Management Private Limited.
Prior to joining Piramal Fund Management Private Limited she has spent more than 30 years at
State Bank of India. She was part of the senior management team at State Bank of India and has
held the posts of General Manager, Enterprise Risk Management at the Corporate Office, as
Representative, Regional Office, Washington D.C. U.S. and as Deputy General Manager and
private secretary at the Chairman’s Secretariat at State Bank of India.Ms. Sudha Ravi is also the
chairperson of ASSOCHAM National Council of Non-Banking Financial Companies.
Ms. Sudha Ravi joined our Board in 2015.
Management Team

Mr. Prabhat Agrawal

Chief Executive Officer

Mr. Prabhat Agrawal, our CEO, graduated from University of Mumbai as Bachelor of
Commerce. He is also a Chartered Accountant, CFA Charter Holder (Chartered Financial
Analyst) and holds a Master’s degree in Business Administration from Indian School of
Business, Hyderabad.
He has been associated with our Company since October, 2014.
He has both Indian and international experience in areas such as corporate strategy, operations
management and financial management including mergers and acquisitions. Prior to joining our
Company he has been associated with Hero Honda Motors Limited, A. F. Ferguson and
Company, Aditya Birla Group, Frigoglass India Private Limited and Metalfrio Solutions S.A.

Mr. Rajesh Dubey

President/CFO

Mr. Rajesh Dubey, our CFO graduated from University of Mumbai as Bachelor of Commerce.
He is also a qualified Chartered Accountant.
He has been associated with our Company since April, 2010.
He has vast experience in audit, taxation and finance. Prior to joining our Company he was
associated with Lupin Limited.
Mr. Manish Narang
President - Legal,Company Secretary and Compliance Officer

Mr. Manish Narang graduated from University of Delhi as Bachelor of Commerce. He also holds
a Bachelor’s degree in Law from Chaudhary Charan Singh University, Meerut. He is also a
qualified Company Secretary and holds a Master’s degree in Management Sciences from
University of Pune.
He has been associated with our Company since November, 2006.
Prior to joining our Company he was associated with Win-Medicare Private Limited and
Western India Sugar Chemical Industry Limited.